Department of Clinical Sciences, Cardiology, Karolinska Institutet, Danderyd Hospital, Stockholm, Sweden.
Department of Health, Medicine and Caring Sciences and Department of Cardiology, Linköping University, Linköping, Sweden.
JAMA Netw Open. 2022 Aug 1;5(8):e2220030. doi: 10.1001/jamanetworkopen.2022.20030.
Antithrombotic treatment after myocardial infarction (MI) should be individualized based on the patient's risk of ischemic and bleeding events. Uncertainty remains regarding the relative prognostic importance of the 2 types of events, and further study would be useful.
To compare the association of ischemic vs bleeding events with mortality in patients with a recent MI and assess whether the relative mortality risk for the 2 types of events has changed over the past 2 decades.
DESIGN, SETTING, AND PARTICIPANTS: A cohort study based on nationwide registers in Sweden, 2012-2017, was conducted. Data were analyzed between July 2021 and May 2022. Patients with MI who were discharged alive with antithrombotic therapy (antiplatelet therapy or oral anticoagulation) were included in the analysis.
The incidence of a first ischemic event (hospitalization for MI or ischemic stroke) or bleeding event (hospitalization with bleeding) up to 1 year after discharge and the mortality risk up to 1 year after each type of event were assessed. Cox proportional hazards regression models were used to estimate adjusted hazard ratios (aHRs) for 1-year mortality after an ischemic and bleeding event vs no event, and after an ischemic vs bleeding event. Adjusted HRs for mortality after ischemic vs bleeding events were compared among patients discharged in 1997-2000, 2001-2011, and 2012-2017.
Of 86 736 patients discharged after MI in 2012-2017 (median age, 71 [IQR, 62-80] years; 57 287 [66.0%] men), 4039 individuals experienced a first ischemic event (5.7 per 100 person-years) and 3399 experienced a first bleeding event (4.8 per 100 person-years). The mortality rate was 46.2 per 100 person-years after an ischemic event and 27.1 per 100 person-years after a bleeding event. The aHR for 1-year mortality vs no event was 4.16 (95% CI, 3.91-4.43) after an ischemic event and 3.43 (95% CI, 3.17-3.71) after a bleeding event. When the 2 types of events were compared, the aHR was 1.27 (95% CI, 1.15-1.40) for an ischemic vs bleeding event. There was no statistically significant difference in the aHR of an ischemic vs bleeding event in 1997-2000, 2001-2011, and 2012-2017.
In this nationwide cohort study of patients with a recent MI, postdischarge ischemic events were more common and associated with higher mortality risk compared with bleeding events.
心肌梗死(MI)后的抗血栓治疗应根据患者发生缺血性和出血性事件的风险进行个体化。关于这两种类型的事件的相对预后重要性仍存在不确定性,进一步的研究将是有用的。
比较近期 MI 患者缺血性与出血性事件与死亡率的关系,并评估这两种类型的事件的相对死亡率风险在过去 20 年中是否发生了变化。
设计、设置和参与者:在瑞典进行了一项基于全国登记册的队列研究,时间为 2012-2017 年。数据分析于 2021 年 7 月至 2022 年 5 月进行。纳入了接受抗血小板治疗(抗血小板治疗或口服抗凝治疗)出院后存活的 MI 患者。
评估出院后 1 年内首次缺血性事件(MI 或缺血性卒中住院)或出血性事件(出血住院)的发生率,以及每种事件后 1 年内的死亡风险。使用 Cox 比例风险回归模型估计缺血性和出血性事件后 1 年死亡率相对于无事件的调整后危险比(aHR),以及缺血性事件后 1 年死亡率相对于出血性事件的 aHR。比较了 1997-2000 年、2001-2011 年和 2012-2017 年出院的患者中缺血性事件与出血性事件后死亡率的调整 HR。
在 2012-2017 年出院的 86736 例 MI 患者中(中位年龄 71[IQR,62-80]岁;57287[66.0%]为男性),4039 例患者发生首次缺血性事件(每 100 人年 5.7 例),3399 例患者发生首次出血性事件(每 100 人年 4.8 例)。缺血性事件后死亡率为 46.2/100 人年,出血性事件后死亡率为 27.1/100 人年。缺血性事件后 1 年死亡率相对于无事件的 aHR 为 4.16(95%CI,3.91-4.43),出血性事件后 1 年死亡率相对于无事件的 aHR 为 3.43(95%CI,3.17-3.71)。当比较这两种类型的事件时,缺血性事件相对于出血性事件的 aHR 为 1.27(95%CI,1.15-1.40)。1997-2000 年、2001-2011 年和 2012-2017 年,缺血性事件相对于出血性事件的 aHR 无统计学显著差异。
在这项针对近期 MI 患者的全国性队列研究中,与出血性事件相比,出院后缺血性事件更为常见,且与更高的死亡率风险相关。